Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17045459 | 0.70 | PKM (0.44) | MEN1KMT2ALMNAALDH1A1HPGD | |
| SCHEMBL10274571 | 0.67 | PKM (0.46) | PDE10AHSD17B10TSHRLMNAL3MBTL1 | |
| SCHEMBL24483396 | 0.66 | NPC1 (0.51) | HSD17B10KMT2ALMNAALDH1A1HPGD | |
| SCHEMBL18693671 | 0.66 | NPC1 (0.47) | HSD17B10LMNAALDH1A1HPGDPKM | |
| SCHEMBL18693143 | 0.65 | NPC1 (0.50) | HSD17B10LMNAALDH1A1HPGDPKM | |
| SCHEMBL16856925 | 0.64 | HSD17B10 (0.36) | PDE10AHSD17B10MEN1TSHRKMT2A | |
| SCHEMBL14785716 | 0.64 | POLB (0.41) | HSD17B10MEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL3366428 | 0.64 | PARP1 (0.49) | HSD17B10MEN1TSHRKMT2AALDH1A1 | |
| SCHEMBL18019665 | 0.63 | NUDT1 (0.63) | ADORA2AADORA1 | |
| SCHEMBL20689399 | 0.62 | L3MBTL1 (0.49) | PDE10AHSD17B10MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635570-A2 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3998261-B1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250034119-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2025-01-30 | — | — | US | disclosed |
| US-11834439-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-11591316-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3998261-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220135546-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114315819-A | Pyrimidin-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for the treatment of neurodegenerative disorders | 戴纳立制药公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-109311857-B | Pyrimidin-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for the treatment of neurodegenerative disorders | 戴纳立制药公司 | 2021-11-12 | — | — | CN | disclosed |
| US-11111235-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210002260-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10590114-B2 | Compounds, compositions, and methods | Denali Therapautics Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3472153-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-109311857-A | Pyrimidin-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for the treatment of neurodegenerative disorders | 戴纳立制药公司 | 2019-02-05 | — | — | CN | disclosed |
| US-20180208582-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9932325-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180051009-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-02-22 | — | — | US | disclosed |
| US-20170362206-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2017218843-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC. (US) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362206-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-20180208582-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-20250034119-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-20210002260-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-10590114-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-11591316-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-11834439-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-20220135546-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-20180051009-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
| US-11111235-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | PDE10A 967/4885HSD17B10 2609/4885MEN1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.